Full history for every metric is available with a Kvantra account
Genetic Technologies Limited (GTG.AX)
Key financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 1 | 0 | 7 | 10 | 8 | 5 |
| Operating profit | AUD m | -12 | -4 | |||||
| Net profit | AUD m | -6 | -6 | -7 | -7 | -12 | -12 | -10 |
| EPS reported | AUD | -0.09 | -0.07 | |||||
| Operating cashflow per share | AUD | -0.07 | -0.07 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.07 | -0.07 | |||||
| Free cash flow | AUD m | -10 | -6 | |||||
| Net debt | AUD m | -0 | -1 | |||||
| Book value equity | AUD m | 2 | -2 | |||||
| Book value per share | AUD | 0.01 | -0.02 | |||||
| Number of shares | m | 138.37 | 144.27 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 6.12 | -2.61 | |||||
| P/S LTM | x | 1.46 | 1.09 | |||||
| P/FCF LTM | x | -1.15 | -0.99 | |||||
| EV/EBITDA LTM | x | -0.97 | -0.78 | |||||
| EV/Sales LTM | x | 1.44 | 0.99 | |||||
| Earnings Yield LTM | % | -107.22% | -222.69% | |||||
| FCF Yield | % | -86.65% | -101.39% | |||||
| Quality | ||||||||
| ROE | % | -656.53% | -184.98% | |||||
| ROIC | % | -429.43% | -429.43% | |||||
| Operating margin | % | -159.30% | -159.30% | |||||
| Gross margin | % | 50.94% | 50.94% | |||||
| FCF/Sales | % | -126.71% | -126.71% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -25.93% | -38.60% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -11.10 | -11.50 | |||||
| Net Debt/EBITDA | x | 0.01 | 0.01 | |||||
| EBIT/Net interest | x | -236.53 | -236.53 | |||||
| Net debt/market cap | % | -3.36% | -9.04% | |||||
| Net debt/Equity | x | -0.21 | 0.24 | |||||
| Gross debt/equity | x | 0.48 | -0.23 | |||||
Company overview
Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Genetic Technologies Limited (GTG.AX)
Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free